Barrington Research Analysts Boost Earnings Estimates for Henry Schein, Inc. (HSIC)
Henry Schein, Inc. (NASDAQ:HSIC) – Equities research analysts at Barrington Research upped their Q3 2017 earnings per share (EPS) estimates for Henry Schein in a note issued to investors on Wednesday. Barrington Research analyst M. Petusky now anticipates that the company will earn $1.79 per share for the quarter, up from their previous estimate of $1.78. Barrington Research currently has a “Outperform” rating and a $198.00 price objective on the stock. Barrington Research also issued estimates for Henry Schein’s Q1 2018 earnings at $1.87 EPS, Q2 2018 earnings at $1.94 EPS, Q4 2018 earnings at $2.22 EPS, FY2018 earnings at $8.00 EPS and FY2019 earnings at $8.80 EPS.
Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share for the quarter, beating analysts’ consensus estimates of $1.73 by $0.02. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The business had revenue of $3.06 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the firm earned $1.64 earnings per share. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year.
Several other research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Henry Schein from a “buy” rating to a “hold” rating in a report on Friday, June 23rd. Stifel Nicolaus restated a “hold” rating on shares of Henry Schein in a report on Thursday, July 6th. Piper Jaffray Companies started coverage on shares of Henry Schein in a report on Monday, June 12th. They set a “neutral” rating and a $200.00 price objective on the stock. Finally, Credit Suisse Group restated a “hold” rating and set a $160.00 price objective on shares of Henry Schein in a report on Thursday, July 13th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have issued a buy rating to the company’s stock. Henry Schein currently has a consensus rating of “Hold” and a consensus price target of $185.56.
Henry Schein (NASDAQ HSIC) opened at 167.32 on Friday. The stock has a 50 day moving average of $181.94 and a 200-day moving average of $175.01. Henry Schein has a 12 month low of $146.23 and a 12 month high of $186.99. The company has a market cap of $13.25 billion, a P/E ratio of 24.45 and a beta of 1.09.
Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Henry Schein by 2,999.6% in the first quarter. BlackRock Inc. now owns 5,595,279 shares of the company’s stock valued at $951,028,000 after buying an additional 5,414,761 shares in the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in shares of Henry Schein during the first quarter valued at approximately $50,281,000. Marshall Wace North America L.P. purchased a new stake in shares of Henry Schein during the first quarter valued at approximately $50,281,000. PGGM Investments purchased a new stake in shares of Henry Schein during the second quarter valued at approximately $32,623,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Henry Schein by 12.4% in the first quarter. JPMorgan Chase & Co. now owns 1,515,861 shares of the company’s stock valued at $257,650,000 after buying an additional 167,213 shares in the last quarter. Institutional investors own 90.87% of the company’s stock.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.